Study of Panobinostat in Patients With Neuroendocrine Tumors
Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This summary will use Panobinostat (LBH589) in patients with neuroendocrine tumors to see how
the patient's tumor responds to panobinostat. Additionally, this study will examine how long
it takes neuroendocrine tumor patient's cancer to progress while taking the drug and examine
the overall survival of patients using panobinostat. Also, the study will examine the
toxicity and tolerability of panobinostat in the patient population. Finally, this study will
look at the effect of panobinostat on Notch 1 signaling before and after treatment with
panobinostat.